Aligos Therapeutics (NASDAQ:ALGS) Issues Quarterly Earnings Results

Aligos Therapeutics (NASDAQ:ALGS) announced its quarterly earnings data on Thursday. The company reported ($2.21) earnings per share for the quarter, beating the consensus estimate of ($2.29) by $0.08, FiscalAI reports. The firm had revenue of $2.83 million during the quarter, compared to analysts’ expectations of $0.25 million. Aligos Therapeutics had a negative return on equity of 28.16% and a negative net margin of 1,106.72%.

Aligos Therapeutics Stock Down 5.3%

Shares of ALGS traded down $0.34 during midday trading on Thursday, hitting $6.03. The company’s stock had a trading volume of 87,644 shares, compared to its average volume of 454,505. Aligos Therapeutics has a one year low of $4.20 and a one year high of $13.69. The company’s fifty day simple moving average is $7.10 and its two-hundred day simple moving average is $8.16. The stock has a market capitalization of $37.33 million, a price-to-earnings ratio of -0.70 and a beta of 2.28.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ALGS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Monday, April 20th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Aligos Therapeutics in a report on Wednesday, March 11th. Wall Street Zen lowered Aligos Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Jefferies Financial Group upgraded Aligos Therapeutics to a “strong-buy” rating in a research note on Thursday, March 26th. Finally, UBS Group initiated coverage on Aligos Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $20.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Aligos Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $41.50.

Hedge Funds Weigh In On Aligos Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ALGS. Woodline Partners LP bought a new stake in Aligos Therapeutics during the 1st quarter worth $2,602,000. Marshall Wace LLP bought a new stake in Aligos Therapeutics during the 4th quarter worth $2,504,000. Vanguard Group Inc. grew its position in Aligos Therapeutics by 22.8% during the 3rd quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock worth $1,683,000 after acquiring an additional 31,913 shares during the last quarter. SummitTX Capital L.P. bought a new stake in Aligos Therapeutics during the 4th quarter worth $1,299,000. Finally, Renaissance Technologies LLC grew its position in Aligos Therapeutics by 55.3% during the 4th quarter. Renaissance Technologies LLC now owns 85,444 shares of the company’s stock worth $796,000 after acquiring an additional 30,425 shares during the last quarter. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.